Intriguingly, the JAK1/2 inhibitor Baricitinib, which also targets the kinase AAK1, a regulator of endocytosis of the SARS-CoV-2 receptor ACE2, had been predicted as a promising treatment for COVID-19 by artificial intelligence algorithms as early as February 2020 (31). This evidence concerns the gene JAK1 and COVID-19.